SCHEMBL4136304

SCHEMBL4136304

CC(C)C[C@H](NC(=O)C1CCCC1)C(=O)NCCCCNS(=O)(=O)c1ccc(F)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 3/20 0.53
BMP1 P13497 1/20 0.45
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CTSL P07711 3/20 0.43
CCR1 P32246 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
EPHX2 P34913 1/20 0.41
TSHR P16473 1/20 0.41
ADAM17 P78536 1/20 0.41
CACNA1B Q00975 2/20 0.40
TRPV4 Q9HBA0 1/20 0.40
NPC1 O15118 1/20 0.39
CTSV O60911 2/20 0.39
CTSS P25774 2/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5434636 0.98 CAPN1 (0.51) CAPN1BMP1MAPK1SMN1; SMN2CTSL
SCHEMBL4142864 0.89 CAPN1 (0.51) CAPN1BMP1MAPK1SMN1; SMN2CTSL
SCHEMBL4141710 0.89 CAPN1 (0.49) CAPN1BMP1SMN1; SMN2CTSLCCR1
SCHEMBL4142973 0.88 CAPN1 (0.48) CAPN1BMP1SMN1; SMN2CTSLCCR1
SCHEMBL4127287 0.87 CAPN1 (0.47) CAPN1BMP1CTSLCCR1EPHX2
SCHEMBL4130820 0.87 CAPN1 (0.47) CAPN1BMP1CTSLCCR1ADAM17
SCHEMBL5429199 0.87 CAPN1 (0.47) CAPN1BMP1SMN1; SMN2CTSLCCR1
SCHEMBL4129767 0.87 CAPN1 (0.47) CAPN1BMP1CTSLCCR1ADAM17
SCHEMBL4140823 0.86 CAPN1 (0.46) CAPN1BMP1CTSLCCR1ADAM17
SCHEMBL4141985 0.85 CAPN1 (0.46) CAPN1BMP1CTSLCCR1ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US claimed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof TRPV4, TRPC4, TRPV1 CAPN1 2031/4885BMP1 2172/4885MAPK1 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.